Elanco Beats Q3 Estimates, Raises 2026 Guidance on Pet Health Strength
ELAN sits 34% above its 52-week low of $19.4.
Summary
Elanco beat on both lines for Q3 2026: adjusted EPS of $0.27 versus $0.20 consensus and revenue of $1.265 billion, up 11.3% and ahead of the $1.208 billion estimate. Pet Health drove the quarter at $608 million, up 14%, with price up 5% and Zenrelia and Credelio Quattro taking share — Zenrelia posted its largest revenue quarter ever and U.S. sales more than doubled year over year. Management raised full-year 2026 adjusted EPS guidance to $1.17-$1.20 from $1.10-$1.16 and sales to $5.155-$5.180 billion from $5.090-$5.140 billion, both above consensus. The Q4 guide of $0.16-$0.19 EPS and $1.190-$1.215 billion in sales brackets the Street. Shares were up 8.97% at $25.80 on the print, and the company recommitted to its mid-single-digit organic revenue and low-double-digit EPS growth algorithm into 2027.
At the time of this announcement, ELAN was trading at $25.96 on NYSE in the Life Sciences sector, with a market capitalization of approximately $13B. The 52-week trading range was $19.40 to $27.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.